参附注射液治疗老年性心瓣膜病临床分析  

Clinical analysis of Shenfu Injection in treating senile valvular heart disease

作　　者：柳骥戎[1] 刘丽彬[1] 李周玉[1] 

机构地区：[1]自贡市第五人民医院老年科,四川自贡643020

出　　处：《中国医学工程》2015年第8期24-25,共2页China Medical Engineering

摘　　要：目的探讨参附注射液对老年性心瓣膜病临床治疗作用。方法选择60例老年性心瓣膜病随机分为治疗组和对照组两组,各30例。治疗组采用5%葡萄糖注射液250 m L+参附注射液60 m L静脉滴注,每天1次,疗程10 d;对照组采用5%葡萄糖注射液250 m L+丹参注射液20 m L静脉滴注,每天1次,疗程10 d。其他治疗用药两组相同。结果连续治疗10 d后,治疗组6 min步行试验(120±5.1)m,心脏彩超LEVF(0.70±0.07),脑钠肽(130±5.3)pg/m L,对照组6 min步行试验(100±4.5)m,心脏彩超LEVF(0.62±0.05),脑钠肽(180±4.5)pg/m L,差异有显著统计学意义(P<0.05)。结论参附注射液治疗老年性心瓣膜病疗效明显优于丹参注射液,值得临床推广。【Objective】To explore the clinical therapeutic effect of Shenfu Injection on senile valvular heart disease. 【Methods】60 cases with senile valvular heart disease were randomly divided into two groups. There were 30 cases in the treatment group and 30 cases in the control group. Patients of treatment group received 250 m L of 5% glucose injection and 60 ml of Shenfu Injection by intravenous drip once a day for 10 days and that of the control group received 250 ml 5% glucose injection and 20 m L Danshen injection by same way. Other drugs of two groups for treatment was same. 【Results】10 days after treatment, the 6 minute walk test was（120±5.1） META, LVEF of echocardiography was（0.70±0.07） and brain natriuretic peptide was（130±5.3） pg/m L in the treatment group, meanwhile that was（100±4.5） m,（0.62±0.05） and（180 ±4.5） pg/m L in the control group. There was significant difference between the two groups（P〈0.05）. 【Conclusion】The effect of Shenfu Injection is obviously better than that of Salvia miltiorrhiza injection in treating senile valvular heart disease that is worth to promote.

关 键 词：参附注射液 老年性心瓣膜病 6 MIN步行试验 左心室射血分数 脑钠肽 

分 类 号：R725.6[医药卫生—儿科]